

INNOVATION Kyoto 2016 LPS Completes Follow-On Strategic Investment in Drawbridge Health

Kyoto, Japan, July 25, 2019 – INNOVATION Kyoto 2016 Limited Liability Partnership (“KYOTO-iCAP 1st Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Koji Murota; “KYOTO-iCAP”), today announced it has completed a follow-on strategic investment in Drawbridge Health Inc. (Headquarters: Menlo Park, CA, US; CEO: Lee McCracken; “Drawbridge”). Participants in the financing include both prior investors GE Ventures and Thorne Research plus new investors Mitsubishi UFJ Capital and Sumitomo Dainippon Pharma.

Drawbridge is a healthcare technology company that is developing a blood sampling solution that enables simplified collection and transportation of dried blood samples for clinical lab testing. The solution is designed to address the painful experience associated with traditional blood collection and to reduce the barriers to obtaining a blood sample, providing an easy way for healthcare providers to collect samples anywhere and anytime, without requiring specialized training. Drawbridge was named “Best MedTech Startup” in the 2018 MedTech Breakthrough Awards⁽¹⁾ and recently presented study results at the American Diabetes Association 79th Annual Scientific Session⁽²⁾.

Drawbridge established a research collaboration with Kyoto University Professor Nobuya Inagaki, M.D., Ph.D., Chairman of the Department of Diabetes, Endocrinology and Nutrition, and Assistant Professor Kaori Ikeda, M.D., Ph.D. at the end of 2018 to advance research and development of the technology in Japan. KYOTO-iCAP anticipates that Drawbridge’s technology will improve human healthcare both in Japan and all over the world.

References:

1. https://drawbridgehealth.com/wp-content/uploads/2018/06/MedTech-Breakthrough_2018-Winner-Release_Drawbridge-Health_Final.pdf
2. Innovative Blood Sampling Technology for Convenient, Nearly Painless, and Accurate Monitoring of Diabetes, Elisa Romeo *et al.*, https://diabetes.diabetesjournals.org/content/68/Supplement_1/231-LB

About Drawbridge Health

Founded in 2015 by GE Ventures and GE Healthcare, Drawbridge Health is a healthcare technology company focused on reinventing the blood sampling paradigm, enabling comfortable and convenient blood sample collection anytime and anywhere. By integrating engineering and proprietary chemistries, Drawbridge is developing a people-friendly system for collecting and stabilizing blood samples, opening new doors to enable access to important health information. For more information, please visit www.drawbridgehealth.com.

About Kyoto University Innovation Capital Co., Ltd. (“Kyoto iCAP”)

Kyoto iCAP is a wholly owned subsidiary of Kyoto University established in December 2014. Its purpose is to provide investment and support to companies founded by researchers belonging to Kyoto University (including spin-offs from joint research companies) for commercializing knowledge (including research results, technology, etc.). The KYOTO-iCAP 1st Fund was created from a 16-billion-yen capital contribution from Kyoto University and private financial institutions, in January 2016. KYOTO-iCAP is a general partner of the Fund. The fund management period is 15 years, that enables KYOTO-iCAP to support Kyoto University-originated ventures with long-term and to provide equity from the seed stage to practical application. The university is one of the top research institutions in Asia.

【Contact Information】

Kyoto University Innovation Capital Co., Ltd.

36-1 Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317 Japan

Kyoto University International Science Innovation Building, East Building, 4th Floor

Head of Media Relations: Osami Kono

Tel: +81-(0)75-753-7588, Fax: +81-(0)75-753-7592

Email: info@kyoto-unicap.co.jp

Drawbridge Health Inc.

2882 Sand Hill Road, Suite 240

Menlo Park, CA 94025

Head of Marketing: Greg Nagy

Tel: 650-279-3434

Email: gnagy@dbhealth.com